AnaptysBio Swings to $176.4M Net Income in Transition Period on $181.5M Tax Benefit
ANAB has more than doubled off its 52-week low of $13.658.
Summary
AnaptysBio's transition report shows $176.4M net income from continuing operations, driven by a $181.5M tax benefit, and formally documents the completed Spin-Off of First Tracks Biotherapeutics.
Key Events · Earnings and Guidance · ANAB
-
Transition Period Net Income
Net income from continuing operations was $176.4 million for the six months ended June 30, 2026, compared to $16.6 million in the prior year period.
-
Tax Benefit Drives Profitability
A $181.5 million income tax benefit resulted from releasing a valuation allowance on deferred tax assets, reflecting expected future profits from the royalty business.
-
Spin-Off Completed
First Tracks Biotherapeutics was spun off on April 20, 2026, with 29.1 million shares distributed pro rata and $100 million in cash allocated to the new entity.
-
Cash Position
Cash, cash equivalents, and investments totaled $164.1 million as of June 30, 2026, down from $211.6 million at December 31, 2025.
Analysis · ANAB · Life Sciences
The first 10-KT following AnaptysBio's fiscal year change reveals a dramatic swing to profitability from continuing operations, with net income of $176.4 million for the six months ended June 30, 2026. Almost the entire result stems from a $181.5 million non-cash income tax benefit from releasing a valuation allowance on deferred tax assets, reflecting management's expectation of future profits from the retained royalty business. The filing also formally documents the completed Spin-Off of First Tracks Biotherapeutics, which distributed 29.1 million shares and $100 million in cash, leaving AnaptysBio as a lean royalty management company with $164.1 million in cash and investments. The ongoing GSK litigation remains a key risk, with post-trial argument scheduled for October 20, 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $55.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $13.66 to $72.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.